JP2017511372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511372A5 JP2017511372A5 JP2016562965A JP2016562965A JP2017511372A5 JP 2017511372 A5 JP2017511372 A5 JP 2017511372A5 JP 2016562965 A JP2016562965 A JP 2016562965A JP 2016562965 A JP2016562965 A JP 2016562965A JP 2017511372 A5 JP2017511372 A5 JP 2017511372A5
- Authority
- JP
- Japan
- Prior art keywords
- period
- addnj
- given
- day
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 239000002552 dosage form Substances 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- 230000007306 turnover Effects 0.000 claims description 11
- GBRAQQUMMCVTAV-LXGUWJNJSA-N n-[(3s,4r,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)piperidin-3-yl]acetamide Chemical compound CC(=O)N[C@H]1CN[C@H](CO)[C@@H](O)[C@@H]1O GBRAQQUMMCVTAV-LXGUWJNJSA-N 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 15
- 208000024827 Alzheimer disease Diseases 0.000 claims 9
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 9
- BTEHIRWQUADKFP-DUVQVXGLSA-N (4r,5r,6r)-6-(hydroxymethyl)piperidine-2,4,5-triol Chemical compound OC[C@H]1NC(O)C[C@@H](O)[C@@H]1O BTEHIRWQUADKFP-DUVQVXGLSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461979408P | 2014-04-14 | 2014-04-14 | |
| US61/979,408 | 2014-04-14 | ||
| US14/684,967 | 2015-04-13 | ||
| US14/684,967 US9675627B2 (en) | 2014-04-14 | 2015-04-13 | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| PCT/US2015/025733 WO2015160796A1 (en) | 2014-04-14 | 2015-04-14 | Dosing regimens for treating and/or preventing cerebral amyloidoses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511372A JP2017511372A (ja) | 2017-04-20 |
| JP2017511372A5 true JP2017511372A5 (enExample) | 2019-05-09 |
| JP6662789B2 JP6662789B2 (ja) | 2020-03-11 |
Family
ID=53015935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562965A Expired - Fee Related JP6662789B2 (ja) | 2014-04-14 | 2015-04-14 | 脳アミロイドーシスを処置及び／又は予防する投与計画 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9675627B2 (enExample) |
| EP (1) | EP3131547A1 (enExample) |
| JP (1) | JP6662789B2 (enExample) |
| KR (1) | KR20170003576A (enExample) |
| CN (1) | CN107148270A (enExample) |
| AU (1) | AU2015247859B2 (enExample) |
| CA (1) | CA2945707A1 (enExample) |
| HK (1) | HK1243643A1 (enExample) |
| SG (1) | SG11201610349SA (enExample) |
| WO (1) | WO2015160796A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6061677B2 (ja) * | 2009-10-19 | 2017-01-18 | アミカス セラピューティックス インコーポレイテッド | 薬理シャペロンを用いてガングリオシドの活性を増大させて、アルツハイマー病を治療するための方法 |
| US9994589B2 (en) | 2015-12-14 | 2018-06-12 | Amicus Therapeutics, Inc. | Compounds and methods for the treatment of alzheimer's disease and/or cerebral amyloid angiopathy |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| US5766846A (en) | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| ATE220327T1 (de) | 1992-09-29 | 2002-07-15 | Inhale Therapeutic Syst | Pulmonale abgabe von aktiven fragmenten des parathormons |
| FR2718357B1 (fr) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Perfectionnements apportés à un dispositif d'injection par jet sans aiguille. |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| WO2004103368A1 (en) | 2003-05-22 | 2004-12-02 | The Hospital For Sick Children | Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| MX2007015602A (es) | 2005-06-08 | 2008-02-21 | Amicus Therapeutics Inc | Tratamiento de trastornos del sistema nervioso central asociados con mutaciones en genes que codifican las enzimas lisosomicas. |
| JP2009537149A (ja) * | 2006-05-16 | 2009-10-29 | アミークス セラピューティックス インコーポレイテッド | ファブリー病に対する治療の選択を診断し、評価するためのアッセイ |
| ATE555788T1 (de) | 2006-06-23 | 2012-05-15 | Amicus Therapeutics Inc | Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität |
| WO2008134628A2 (en) | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| WO2011011181A1 (en) | 2009-07-01 | 2011-01-27 | Amicus Therapeutics, Inc. | Pharmacological chaperones for the treatment of alzheimer's disease |
| JP6061677B2 (ja) | 2009-10-19 | 2017-01-18 | アミカス セラピューティックス インコーポレイテッド | 薬理シャペロンを用いてガングリオシドの活性を増大させて、アルツハイマー病を治療するための方法 |
| US20140219986A1 (en) * | 2011-03-11 | 2014-08-07 | Amicus Therapeutics ,Inc. | Dosing regimens for the treatment of fabry disease |
| ES2864774T3 (es) * | 2011-12-22 | 2021-10-14 | Centogene Ip Gmbh | Combinación de un compuesto que tiene la capacidad de reorganizar una enzima lisosomal y Ambroxol y/o un derivado de Ambroxol |
| EP2844279B1 (en) * | 2012-05-03 | 2020-12-09 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of pompe disease |
-
2015
- 2015-04-13 US US14/684,967 patent/US9675627B2/en active Active
- 2015-04-14 WO PCT/US2015/025733 patent/WO2015160796A1/en not_active Ceased
- 2015-04-14 CN CN201580031471.1A patent/CN107148270A/zh active Pending
- 2015-04-14 SG SG11201610349SA patent/SG11201610349SA/en unknown
- 2015-04-14 KR KR1020167031756A patent/KR20170003576A/ko not_active Withdrawn
- 2015-04-14 CA CA2945707A patent/CA2945707A1/en not_active Abandoned
- 2015-04-14 HK HK18103256.3A patent/HK1243643A1/zh unknown
- 2015-04-14 AU AU2015247859A patent/AU2015247859B2/en not_active Ceased
- 2015-04-14 JP JP2016562965A patent/JP6662789B2/ja not_active Expired - Fee Related
- 2015-04-14 EP EP15719362.4A patent/EP3131547A1/en not_active Withdrawn
-
2017
- 2017-06-12 US US15/619,785 patent/US20170273996A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114008035A (zh) | 一种shp2磷酸酶变构抑制剂 | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| MX2014002459A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
| Scammell et al. | Coexistence of narcolepsy and Alzheimer's disease | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2016087944A3 (en) | Method for treating alzheimer's disease | |
| MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
| JP2025137763A (ja) | 絶食条件下でのタシメルテオンの投与 | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| Sabbagh et al. | Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response | |
| JP2017501848A5 (enExample) | ||
| CN110114083A (zh) | 一种预防和治疗脂肪肝的方法 | |
| JP2018530578A5 (enExample) | ||
| JP2016530265A5 (enExample) | ||
| JP2016510343A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| JP2017533220A5 (enExample) | ||
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| JP2014507475A5 (enExample) | ||
| Abuduli et al. | Role of traditional and complementary medicine in universal coverage | |
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| JP2016505561A5 (enExample) | ||
| JP2021512086A5 (enExample) | ||
| JP2018505901A5 (enExample) |